← Leaderboards
Xuebin Qin
Harvard University (Medical School)
$11,917,384
Attributed
$14,703,755
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,703,755 · 10
By mechanism
R01$13,232,137 · 6
R21$1,471,618 · 4
Top collaborators
- Tricia Helen Burdo4 shared
- Hong Wang4 shared
- Sulie Lin Chang3 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMediatingComplementTransgenic MiceTransgenic OrganismsIn VitroMacrophageComplement Membrane Attack ComplexIn VivoMolecularMetabolicHemolysisAntibodiesErythrocytesAtherosclerosisAnimal ModelFosteringResponsePathogenesisDesignInhibitor/AntagonistImmunePathologicTissues
Grant awards (35)
Role of Complement Activation in Severe COVID-19$674,370
R01 · FY2025 · HL · contact PI
Renal Macrophage Biology$460,227
R01 · FY2025 · DK · contact PI
Role of Complement Activation in Severe COVID-19$660,854
R01 · FY2024 · HL · contact PI
Renal Macrophage Biology$490,708
R01 · FY2024 · DK · contact PI
Role of Complement Activation in Severe COVID-19$674,314
R01 · FY2023 · HL · contact PI
Renal Macrophage Biology$510,944
R01 · FY2023 · DK · contact PI
Role of Complement Activation in Severe COVID-19$186,595
R01 · FY2023 · HL · contact PI
Role of Complement Activation in Severe COVID-19$690,773
R01 · FY2022 · HL · contact PI
Renal Macrophage Biology$510,738
R01 · FY2022 · DK · contact PI
Role of caspase-1 activation in HIV-1 associated atherogenesis$612,974
R01 · FY2021 · HL
Role of caspase-1 activation in HIV-1 associated atherogenesis$612,874
R01 · FY2020 · HL
Role of caspase-1 activation in HIV-1 associated atherogenesis$610,461
R01 · FY2019 · HL
Atherogenic roles of complement system$596,598
R01 · FY2019 · HL
Generation and Characterization of a Novel Cell Subpopulation Ablation Model$212,500
R21 · FY2019 · OD · contact PI
Role of caspase-1 activation in HIV-1 associated atherogenesis$646,706
R01 · FY2018 · HL · contact PI
Atherogenic roles of complement system$608,176
R01 · FY2018 · HL · contact PI
Generation and characterization of a novel cell subpopulation ablation model$237,750
R21 · FY2018 · OD · contact PI
Methamphetamine actions on recovery of the BBB damage related to HIV$227,007
R21 · FY2018 · DA
Alcohol-induced Impairment of Endothelial Cell Recovery$179,599
R21 · FY2018 · AA
Atherogenic roles of complement system$618,906
R01 · FY2017 · HL · contact PI
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies$327,938
R01 · FY2017 · CA · contact PI
Alcohol-induced Impairment of Endothelial Cell Recovery$215,869
R21 · FY2017 · AA
Atherogenic roles of complement system$643,572
R01 · FY2016 · HL · contact PI
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies$327,938
R01 · FY2016 · CA · contact PI
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies$327,872
R01 · FY2015 · CA · contact PI
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies$324,825
R01 · FY2014 · CA · contact PI
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies$223,660
R01 · FY2013 · CA · contact PI
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies$119,146
R01 · FY2013 · CA · contact PI
Abrogating human CD59 activity for antibody-based cancer therapy$214,562
R21 · FY2011 · CA · contact PI
Abrogating human CD59 activity for antibody-based cancer therapy$184,331
R21 · FY2010 · CA · contact PI
Towards a Mouse Model of Complement-Mediated Diseases$389,815
R01 · FY2009 · AI · contact PI
Towards a Mouse Model of Complement-Mediated Diseases$389,686
R01 · FY2008 · AI · contact PI
Towards a Mouse Model of Complement-Mediated Diseases$321,433
R01 · FY2007 · AI · contact PI
Towards a Mouse Model of Complement-Mediated Diseases$331,034
R01 · FY2006 · AI · contact PI
Towards a Mouse Model of Complement-Mediated Diseases$339,000
R01 · FY2005 · AI